| Patents for A61P 39 - General protective or antinoxious agents (19,019) |
|---|
| 02/28/2002 | CA2420179A1 Composition and method for inhibiting platelet aggregation |
| 02/28/2002 | CA2420024A1 Fused pyrazole derivatives being protein kinase inhibitors |
| 02/28/2002 | CA2419840A1 Treatment of hyperproliferative diseases |
| 02/27/2002 | EP1181049A1 Cardioprotective composition comprising ceruloplasmin and uses thereof |
| 02/27/2002 | EP1181035A2 Substantially oil-free cyclosporin compositions |
| 02/27/2002 | CN1337257A Application of compound Dashen drip pills in preparing antioxidant medicine |
| 02/27/2002 | CN1079668C Injectable liposumal pharmaceutical preparation |
| 02/26/2002 | US6350744 Pyrmidine or pyridine derivatives; antiarthritic and antiinflammatory agents; cachexia treatment; interleukin and tumor necrosis factor inhibitors |
| 02/21/2002 | WO2002013632A1 Selenium diet supplement |
| 02/21/2002 | WO2001085256A3 Critical illness neuropathy |
| 02/21/2002 | WO2001079443A3 Albumin fusion proteins |
| 02/21/2002 | WO2001078533A3 Nutritional modules |
| 02/21/2002 | WO2001072291A3 Treatment of movement disorders with metabotropic glutamate receptor antagonist |
| 02/21/2002 | WO2001068802A3 Genes of il-12p40 subunit mutated for improving the activity of il-12 and use thereof for dna vaccine adjuvant |
| 02/21/2002 | WO2001019158A3 An anti-oxidant preparation based on plant extracts for the treatment of circulation and adiposity problems |
| 02/21/2002 | US20020022654 Method for increasing the concentration of ascorbic acid in brain tissues of a subject |
| 02/21/2002 | US20020022035 Genetic engineering; deactivating toxin |
| 02/21/2002 | CA2420080A1 Selenium diet supplement |
| 02/20/2002 | CN1336208A Compound garlic powder for eliminating toxic metals from human body |
| 02/20/2002 | CN1079198C Health-care and pungent taste tea contg. leaves of hot spice plant |
| 02/19/2002 | US6348214 Materials and methods for making improved liposome compositions |
| 02/14/2002 | WO2002012506A1 Lactobacillus rhamnosus polynucleotides, polypeptides and methods for using them |
| 02/14/2002 | WO2002011753A1 Protein injection preparations |
| 02/14/2002 | WO2002011744A1 A strong antioxidant composite capsule containing grape seed extract opc and process for producing the same |
| 02/14/2002 | WO2002011724A2 Neuroprotective 2-pyridinamine compositions and related methods |
| 02/14/2002 | WO2002011715A2 The use of benzylideneaminoguanidines and hydroxyguanidines as melanocortin receptor ligands |
| 02/14/2002 | WO2001042288A3 G-protein coupled receptors |
| 02/14/2002 | WO2000043395A8 Substituted porphyrins |
| 02/14/2002 | US20020019563 A S-(2-(1-iminoethyl)amino)ethyl)-2-methyl-L-cysteine |
| 02/14/2002 | US20020019424 1-sulfonyl pyrrolidine derivatives |
| 02/14/2002 | US20020018807 Mixture of cocoa plant extract and antichloesterol agent |
| 02/14/2002 | DE10038640A1 Präparat mit gefäßschützender und antioxidativer Wirkung sowie dessen Verwendung Preparation with vascular protective and antioxidant activity and its use |
| 02/14/2002 | CA2418912A1 Neuroprotective 2-pyridinamine compositions and related methods |
| 02/14/2002 | CA2417098A1 The use of benzylideneaminoguanidines and hydroxyguanidines as melanocortin receptor ligands |
| 02/14/2002 | CA2416982A1 Lactobacillus rhamnosus polynucleotides, polypeptides and methods for using them |
| 02/13/2002 | EP1179022A2 Bufornin 1 as a specific inhibitor and therapeutic agent for botulinum toxin b and tetanus neurotoxins |
| 02/13/2002 | EP1179010A2 Previns as specific inhibitors and therapeutic agents for botulinum toxin b and tetanus neurotoxins |
| 02/13/2002 | EP1179008A2 Tetrapeptide revealing geroprotective effect, pharmacological substance on its basis, and the method of its application |
| 02/13/2002 | EP1178796A1 Salts of aminoimidazole carboxamide useful in the prevention and treatment of liver diseases |
| 02/13/2002 | CN1335141A Antiaging water containing natural medicinal component and its prepn |
| 02/13/2002 | CN1335140A Medicine bolus for dredging meridian passage, nourishing blood and removing toxic material |
| 02/07/2002 | WO2002010148A1 Novel coumarin derivatives and the salts thereof, a process for the preparation thereof and their use in the pharmaceutical field |
| 02/07/2002 | WO2002010139A1 Hexahydro-7-1h-azepin-2-yl-haxanoic acid derivatives as inhibitors of inducible nitric oxide synthase |
| 02/07/2002 | WO2002009723A2 Ammonium salts of hemoglobin allosteric effectors, and uses thereof |
| 02/07/2002 | WO2002009678A2 Charged phospholipid compositions and methods for their use |
| 02/07/2002 | WO2001062744A3 Substituted piperazine compounds |
| 02/07/2002 | US20020016532 Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug |
| 02/07/2002 | US20020016311 Nitrate esters and their use for neurological conditions |
| 02/07/2002 | US20020015687 Method for the anhydrous loading of nicotine onto ion exchange resins |
| 02/07/2002 | CA2455170A1 Charged phospholipid compositions and methods for their use |
| 02/07/2002 | CA2417788A1 Novel coumarin derivatives and the salts thereof, a process for the preparation thereof and their use in the pharmaceutical field |
| 02/07/2002 | CA2415851A1 Hexahydro-7-1h-azepin-2-yl-haxanoic acid derivatives as inhibitors of inducible nitric oxide synthase |
| 02/06/2002 | EP1177296A2 Extracellular matrix and adhesion-associated proteins |
| 02/06/2002 | EP1177200A1 Ligands for metabotropic glutamate receptors |
| 02/06/2002 | EP1177168A1 Caspase inhibitors and the use thereof |
| 02/06/2002 | EP1176870A2 Tgf-alpha polypeptides, functional fragments and methods of use therefor |
| 02/06/2002 | CN1334084A Medicine composition containing pyrroloquinolinequinone for treating saturnism |
| 02/05/2002 | US6344447 Administering mixture of nucleosides; anticancer agent |
| 02/05/2002 | CA2242373C Teas for the amelioration of the effects of alcoholic drinks and processes for the production thereof |
| 01/31/2002 | WO2002008285A2 Il-17 molecules and uses thereof |
| 01/31/2002 | WO2002008217A2 COUMARIN DERIVATIVES USEFUL AS TNFα INHIBITORS |
| 01/31/2002 | WO2002008182A1 Method for the production of a water-dispersible formulation containing carotenoids |
| 01/31/2002 | WO2002007707A2 Linkage of agents using microparticles |
| 01/31/2002 | WO2002007678A2 Mu-conopeptides |
| 01/31/2002 | US20020013347 Tri-aryl-substituted-ethane PDE4 inhibitors |
| 01/31/2002 | US20020013341 For therapy of acute infection, acute phase response, age related macular degeneration, alcoholism, anorexia, asthma, autoimmune disease, autoimmune hepatitis, Bechet's disease, cachexia, calcium pyrophosphate dihydrtate deposition |
| 01/31/2002 | US20020012715 Protecting cell from damage caused by free radicals by administering lipophilic antioxidant comprising vitamin E, beta carotene, extract of Lycopersicum esculentum, hydrophilic antioxidant comprising vitamin c, extract of vitis vinifera |
| 01/31/2002 | US20020012714 Combined marine and plant extract compositions |
| 01/31/2002 | CA2416544A1 Mu-conopeptides |
| 01/31/2002 | CA2415345A1 Linkage of agents using microparticles |
| 01/31/2002 | CA2412626A1 Il-17 molecules and uses thereof |
| 01/30/2002 | EP1175453A2 Differentially acting op detoxifying sponges |
| 01/30/2002 | EP1175223A2 Methods and compositions for modulating an immune response |
| 01/30/2002 | EP1175212A1 Use of antioxidants to mitigate radioimmunotherapy-induced radiation toxicity |
| 01/30/2002 | EP0819136B1 Mdp derivatives and conjugates having haematopoietic function stimulating activity, and compositions containing same |
| 01/30/2002 | CN1333694A Stable amorphous amifostine compositions and methods for the preparation and use of same |
| 01/30/2002 | CN1078466C New use of sinomenine |
| 01/29/2002 | CA2216789C Method of mucociliary clearance in cystic fibrosis patients using alkylaryl polyether alcohol polymers |
| 01/24/2002 | WO2002006284A1 Indoloquinazolinones |
| 01/24/2002 | WO2002006222A1 Pyrrolidine derivatives as inhibitors of endothelin-converting enzyme |
| 01/24/2002 | WO2001038305A3 Novel il-8 receptor antagonists |
| 01/24/2002 | US20020010357 Heat resistance dosage forms |
| 01/24/2002 | US20020010133 Method for preventing gastritis using amylin or amylin agonists |
| 01/23/2002 | EP1174423A1 Substrates for thioredoxin reductase |
| 01/23/2002 | EP1173757A1 Diagnosis of human kidney diseases |
| 01/23/2002 | EP1173485A1 Human antibodies to staphylococcus aureus |
| 01/23/2002 | EP1173477A1 49 human secreted proteins |
| 01/23/2002 | EP1173439A1 Haloalkoxy imidazonaphthyridines |
| 01/23/2002 | EP1173197A2 Metabolic intervention with glp-1 to improve the function of ischemic and reperfused tissue |
| 01/23/2002 | EP1173158A1 Compounds useful in reducing the level of insulin like growth factor-1 (igf-1) in blood |
| 01/23/2002 | EP0726771B1 Desferrioxamine oral delivery system |
| 01/23/2002 | EP0623144B1 Synthetic peptides for detoxification of bacterial endotoxins and treatment of septic shock |
| 01/23/2002 | CN1332741A Pyrazolopyridine derivatives as selective COX-2 inhibitors |
| 01/17/2002 | WO2002004454A1 Non-genotoxic metalloporphyrins as synthetic catalytic scavengers of reactive oxygen species |
| 01/17/2002 | WO2002004025A1 Production, stabilisation and use of reduced forms of pharmaceutical compounds |
| 01/17/2002 | WO2002003972A2 Therapeutic and prophylactic use of reduced forms of pharmaceutical compounds |
| 01/17/2002 | WO2001059067A3 A group of anti-cancer compounds with specific structure and their production method |
| 01/17/2002 | WO2001058412A3 Extracts from residues left in the production of wine |
| 01/17/2002 | WO2001001973A3 Highly selective norepinephrine reuptake inhibitors and methods of using the same |
| 01/17/2002 | US20020006421 Long-acting, chemical-resistant skin emollients, moisturizers, and strengtheners |